NeXT Dx Test is optimised for formalin-fixed, paraffin-embedded tumour samples, and is performed at its CAP-accredited and CLIA’88-certified laboratory
Personalis, a US-based cancer genomics company, has launched the NeXT Dx Test, designed to help oncologists in identifying cancer therapies and clinical trial options.
The company claimed that its NeXT Dx Test is the first cancer diagnostic platform capable of profiling approximately 20,000 genes in both the tumour exome and transcriptome.
In addition, the test is said to provide a complete genomic testing solution, outperforming various available cancer diagnostic panels focused on a few hundred genes.
Personalis chief scientific officer Richard Chen said: “With new cancer immunotherapy and combination therapies, there is an increasing need for the development of more advanced composite biomarkers that can model the complex biology driving the response and resistance to cancer therapy.
“Our NeXT Dx Test provides oncologists with clinical reports on key diagnostic markers driving therapies today as well as provides information that can support the identification of new, advanced biomarkers.”
Personalis NeXT Dx Test offers a diagnostic report on genetic alterations in cancer genes
Personalis said that its NeXT Dx Test has been designed to use advanced analytics for providing a diagnostic report on genetic alterations in cancer genes.
In addition, the report also includes genetic alterations in advanced immunotherapy composite biomarkers of medical importance, and immunotherapy-related biomarkers including microsatellite instability (MSI) status and tumour mutational burden (TMB).
The company said that its lab-developed test is optimised for formalin-fixed, paraffin-embedded tumour samples, and is performed at its CAP-accredited and CLIA’88-certified laboratory.
The test is said to use ImmunoID NeXT, a clinical-grade sequencing and analysis platform, to report base substitutions, insertions or deletions, gene fusions, and copy number alterations in cancer driver genes.
ImmunoID NeXT platform is designed to consolidate numerous biomarker assays into one, and offers a multidimensional view of the tumour and its microenvironment from a single sample.
The test provides report with therapy recommendations and suitable clinical trial matches, based on molecular profile of the tumour.
Furthermore, a team of certified molecular geneticists and genetic counsellors will review each case, and the test results will be electronically delivered to the clinician who ordered.